Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CURROTCMKTS:CVSINASDAQ:ENLVOTCMKTS:MRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURRCurrenc Group$0.67+11.6%$0.83$0.33▼$7.08$31.18M-0.492.77 million shs1.58 million shsCVSICV Sciences$0.04+1.5%$0.03$0.02▼$0.06$7.39M0.47268,868 shs481,382 shsENLVEnlivex Therapeutics$1.20-0.8%$1.01$0.81▼$1.76$28.38M0.74128,828 shs68,117 shsMRMDMariMed$0.07+2.8%$0.08$0.07▼$0.29$27.29M2.99321,723 shs123,791 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURRCurrenc Group0.00%+57.65%+11.67%-55.63%+66,999,900.00%CVSICV Sciences0.00%+33.33%+45.45%+23.46%-31.62%ENLVEnlivex Therapeutics0.00%+10.09%+24.56%+23.69%-15.49%MRMDMariMed0.00%-0.14%-16.39%-25.64%-61.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCURRCurrenc GroupN/AN/AN/AN/AN/AN/AN/AN/ACVSICV Sciences0.2183 of 5 stars0.03.00.00.02.00.00.0ENLVEnlivex Therapeutics3.2842 of 5 stars3.75.00.00.02.70.80.6MRMDMariMed0.2383 of 5 stars0.03.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURRCurrenc Group 3.50Strong Buy$3.50422.39% UpsideCVSICV Sciences 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.33Buy$10.00733.33% UpsideMRMDMariMed 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest CVSI, ENLV, CURR, and MRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/3/2025MRMDMariMedNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURRCurrenc Group$46.44M0.67N/AN/A($0.90) per share-0.74CVSICV Sciences$15.70M0.47N/AN/A$0.01 per share4.00ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AMRMDMariMed$157.96M0.17$0.02 per share3.24$0.16 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURRCurrenc Group-$39.47MN/A0.00∞N/AN/AN/A-38.11%7/14/2025 (Estimated)CVSICV Sciences-$2.39M-$0.01N/A∞N/A-12.25%-89.43%-22.75%N/AENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)MRMDMariMed-$12.16M-$0.03N/A∞N/A-10.33%-10.21%-3.12%8/6/2025 (Estimated)Latest CVSI, ENLV, CURR, and MRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/20/2025Q1 2025CURRCurrenc Group-$0.04-$0.13-$0.09-$0.13$10.50 million$10.06 million5/7/2025Q1 2025MRMDMariMed-$0.01-$0.01N/A-$0.01$38.33 million$37.96 million4/14/2025Q4 2024CURRCurrenc Group-$0.04-$0.70-$0.66-$0.70$10.50 million$11.07 million3/31/2025Q4 2024ENLVEnlivex Therapeutics-$0.16-$0.23-$0.07-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCURRCurrenc GroupN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURRCurrenc GroupN/A0.610.61CVSICV Sciences0.261.140.30ENLVEnlivex TherapeuticsN/A7.207.20MRMDMariMed1.211.050.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURRCurrenc Group56.01%CVSICV SciencesN/AENLVEnlivex Therapeutics1.02%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipCURRCurrenc Group43.30%CVSICV Sciences1.30%ENLVEnlivex Therapeutics12.28%MRMDMariMed18.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURRCurrenc Group246.53 million26.38 millionN/ACVSICV Sciences70184.79 million182.39 millionNot OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableMRMDMariMed260390.43 million316.29 millionNot OptionableCVSI, ENLV, CURR, and MRMD HeadlinesRecent News About These CompaniesMariMed Inc. (MRMD) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comMariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | uk.finance.yahoo.comMariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | globenewswire.comMariMed Inc.: MariMed Reports First Quarter 2025 EarningsMay 8, 2025 | finanznachrichten.deMariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comMariMed Reports First Quarter 2025 EarningsMay 7, 2025 | globenewswire.comMariMed Announces First Quarter 2025 Earnings DateApril 8, 2025 | globenewswire.comMariMed Promotes Ryan Crandall to Chief Commercial OfficerApril 7, 2025 | globenewswire.comMariMed's Betty's Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel ChewsApril 3, 2025 | globenewswire.comMarimed launches Nature’s Heritage Flower in IllinoisApril 1, 2025 | markets.businessinsider.comMariMed Launches Nature's Heritage™ Flower in IllinoisApril 1, 2025 | globenewswire.comMariMed Inc. (PNK:MRMD) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comMariMed Reports Record Revenue Amid Strategic GrowthMarch 6, 2025 | tipranks.comMariMed has price target chopped at VentumMarch 6, 2025 | cantechletter.comCMariMed Inc. (MRMD) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comMariMed Reports Fourth Quarter and Full Year 2024 EarningsMarch 5, 2025 | globenewswire.comMariMed Completes Acquisition of First State Compassion, Strengthening Market Position in DelawareMarch 3, 2025 | globenewswire.comMariMed Announces Fourth Quarter and Full Year 2024 Earnings DateFebruary 11, 2025 | globenewswire.comMariMed Commences Wholesale Operations in MissouriDecember 23, 2024 | globenewswire.comMariMed Reports Third Quarter 2024 EarningsNovember 6, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryThe Market’s Silent Warning: What Bonds and Gold RevealBy Gabriel Osorio-Mazilli | June 6, 2025View The Market’s Silent Warning: What Bonds and Gold RevealAs Gold Surges, Albemarle Stock May Be the Next to PopBy Gabriel Osorio-Mazilli | June 10, 2025View As Gold Surges, Albemarle Stock May Be the Next to PopAutoNation: Growth Engines Make It an Undervalued Stock By Jeffrey Neal Johnson | June 29, 2025View AutoNation: Growth Engines Make It an Undervalued Stock Why Visa's Innovation Engine Keeps It a Top Portfolio PickBy Jeffrey Neal Johnson | June 6, 2025View Why Visa's Innovation Engine Keeps It a Top Portfolio PickCVSI, ENLV, CURR, and MRMD Company DescriptionsCurrenc Group NASDAQ:CURR$0.67 +0.07 (+11.57%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$0.64 -0.03 (-4.33%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.CV Sciences OTCMKTS:CVSI$0.04 +0.00 (+1.52%) As of 06/27/2025 03:32 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Enlivex Therapeutics NASDAQ:ENLV$1.20 -0.01 (-0.83%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.21 +0.01 (+0.83%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.MariMed OTCMKTS:MRMD$0.07 +0.00 (+2.79%) As of 06/27/2025 03:42 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
